# Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations

> **NCT05082025** · PHASE2 · TERMINATED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 7 (actual)

## Conditions studied

- Endometrial Cancer
- Ovarian Cancer

## Interventions

- **DRUG:** Copanlisib
- **DRUG:** fulvestrant

## Key facts

- **NCT ID:** NCT05082025
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-09-27
- **Primary completion:** 2024-05-03
- **Final completion:** 2025-12-12
- **Target enrollment:** 7 (ACTUAL)
- **Why stopped:** Copanlisib development was discontinued by Bayer following withdrawal of copanlisib in relapsed follicular lymphoma in November 2023.
- **Last updated:** 2026-01-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05082025

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05082025, "Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations". Retrieved via AI Analytics 2026-07-21 from https://api.ai-analytics.org/clinical/NCT05082025. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*